Tags : Bausch + Lomb

Pharma

Bausch Health to Spin off its Eye Health Business

Shots: Bausch Health spin-off its leading eye health business into an independent publicly-traded company under the name Bausch + Lomb. The spinoff is expected to be completed in H1’21 The spinoff will lead to the formation of two separate companies that include an eye-health company built on the iconic Bausch + Lomb brand and a […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (May 04-08, 2020)

1.Fitbit Launches Heart Study to Validate its Wearable Technology for Identifying Atrial Fibrillation Published: May 06, 2020 | Tags: Fitbit, Launches, Heart Study, Validate, Wearable Technology, Identifying, Atrial Fibrillation 2.  Celltrion Launches Remsima SC (biosimilar, infliximab) for the Treatment of Autoimmune Diseases in the Netherlands Published: May 07, 2020 | Tags: Celltrion, Launches, Remsima SC, biosimilar, […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (January 27-31, 2020)

ProQR’s QR-421a Receives FDA’s Rare Pediatric Disease Designation for Retinitis Pigmentosa Published: Jan 30, 2020 | Tags: ProQR, QR-421a, Receives, FDA, Rare Pediatric Disease Designation, Retinitis Pigmentosa 2. Eli Lilly’s Fast-Acting Insulin Lispro Receives CHMP’s Positive Opinion in Patients with Diabetes Published: Jan 31, 2020 | Tags: Eli Lilly, Fast Acting Insulin Lispro, Receives, CHMP, Positive Opinion, […]Read More

MedTech

Bausch + Lomb Collaborates with TerraCycle to Launch First Contact

Shots: The companies will collaboratively launch Bausch + Lomb Every Contact Counts recycling program in eyecare offices across Canada, allowing people to recycle their disposable contact lenses and blister pack packaging The goal of the initiative is to provide an opportunity to eye care professionals and patients to collect waste with an aim to increase […]Read More

Pharma

Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals’

Shots: Bausch + Lomb (Bausch Health’s subsidiary) acquires US commercial rights from Eton Pharmaceuticals for its EM-100, has been evaluated in P-III study vs PBO in patients with ocular itching associated with allergic conjunctivitis, demonstrated no AEs and non-inferiority data The focus of the agreement is to strengthen Bausch’s portfolio of ophthalmology with the expansion […]Read More